A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Capmatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Geometry Mono-1
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 18 Mar 2018 Planned number of patients changed from 399 to 429.
- 07 Feb 2018 Planned primary completion date changed from 4 Sep 2018 to 5 Sep 2018.
- 18 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer